Proprietary peptide technology platform to develop oral targeted therapy-based drugs that work by blocking biological pathways currently targeted by marketed injectable antibody drugs, and injectables for rare diseases. PTG-300 injectable hepcidin mimetic PTG-300 Ph 2 beta-thalassemia initial results expected 4Q19; PN-943 oral GI-restricted alpha-4-beta-7 antagonist Ph 2 in ulcerative colitis to begin in early 2020; and PTG-200, partnered w/ Janssen, oral GI-restricted IL-23R antagonist to begin Ph 2 Crohn’s disease study in 4Q19.
Phase l or ll
Anti-inflammatory, Gastrointestinal, Hematology, Rare Disease
100MM - 500MM
521 Cottonwood Drive
Milpitas, CA 95035
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by